Parkinson's Drug Hits Shelves, Major Event Awaits ABIO In Mar, FDA Nod For NVRO

Today's Daily Dose brings you news about Acceleron's phase II facioscapulohumeral dystrophy trial; Adamas' commercial launch of the first and only FDA-approved medication for the treatment of Dyskinesia in Parkinson's disease patients; ARCA's major upcoming event; Dexcom's preliminary Q4 results and 2018 outlook; Infinity Pharma's near-term catalysts.

from RTT - Biotech http://ift.tt/2CIS920
via IFTTT